HDAC5 modulates PD-L1 expression and cancer immunity via p65 deacetylation in pancreatic cancer

Rationale: Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease with a dismal 5-year survival less than 10%. Most patients with PDAC exhibit poor response to single-agent immunotherapy. Multimodal therapies targeting mechanisms of resistance to immunotherapy are urgently needed. We found that...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Yingke, Jin, Xin, Yu, Haixin, Qin, Gengdu, Pan, Penglin, Zhao, Jingyuan, Chen, Taoyu, Liang, Xueyi, Sun, Yan, Wang, Bo, Ren, Dianyun, Zhu, Shikai, Wu, Heshui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8899586/
https://www.ncbi.nlm.nih.gov/pubmed/35265200
http://dx.doi.org/10.7150/thno.69444

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8899586/
https://www.ncbi.nlm.nih.gov/pubmed/35265200
http://dx.doi.org/10.7150/thno.69444

Ejemplares similares